NewsUpdated 6 min read
FDA's briefing opposed listing seven peptides. What the PCAC meeting changes and what it does not
FDA's briefing recommended against listing BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP. HHS later confirmed the committee voted in favor of the first six.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
Update, October 28, 2026: HHS released a draft enforcement discretion policy covering six of these peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. It is not an FDA approval and does not add them to the bulks list. Read what the HHS draft policy changes. [1]
On July 23 to 24, 2026, FDA presented seven peptides to its Pharmacy Compounding Advisory Committee (PCAC): BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP. FDA's own briefing slides recommended against adding any of them to the 503A bulk drug substances list. [2] For each of the first six, FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). [1]
The short version: the meeting is not a legal change. FDA has proposed no rule, none of the seven is on the bulks list, the evidence behind each peptide is exactly what it was the day before the meeting, and the WADA status of each peptide is untouched. Below is what the meeting actually does, what it does not, and how to read the next steps on our regulatory tracker.
How these peptides got here
Traditional compounding pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy may compound from a bulk ingredient only if it is a component of an FDA approved drug, has a USP or NF monograph, or appears on FDA's list of bulk drug substances that can be used in compounding. [6] FDA builds that list by rulemaking; the first final rule was published in February 2019 and also described the Category 1, 2, and 3 framework FDA uses while nominated substances are evaluated. [5]
In September 2023 FDA placed a large group of nominated peptides, including all seven discussed at the July meeting, in 503A Category 2: substances that raise significant safety risks and may not be compounded while evaluation continues. [3] In April 2026 FDA revised its Category 2 page to move BPC-157 and 16 other peptides to a separate list of nominations withdrawn by their nominators. Withdrawal took them out of Category 2, but it was not an approval and did not add anything to the bulks list. A withdrawn substance is in no 503A category, so FDA's own interim policy for nominated substances does not cover it. HHS's October 2026 draft policy for six of these peptides is a separate document. [1] [3] Seven of those peptides were then taken to the committee in July. [2]
What the meeting changes
The meeting put FDA's own position on the public record: its briefing recommended against listing all seven. The committee is advisory, and for the first six it voted in favor of listing (HHS policy, Appendix B). FDA has proposed no rule. [1] [2]
The meeting itself did not create permission to compound: none of the six is on the 503A bulks list. [4] In October 2026, HHS released a separate draft enforcement discretion policy for the six, which is not a listing or an approval; see our explainer. [1] State rules still apply on top of federal ones, and boards can act on their own: in August 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved. [20] See the state legal guides for your pharmacy board and telehealth rules.
It has not stopped the market either. FDA's briefing documents for the meeting found websites offering KPV from compounding pharmacies through telemedicine, and clinics and online sellers marketing semax and DSIP. [16] [17] [18] FDA has also warned a state-licensed 503A pharmacy that compounded BPC-157, semax, epitalon, and DSIP, among about 20 bulk substances, outside section 503A. [19] Being offered does not make any of them lawful. Each peptide page, starting with BPC-157, explains what that means for you and what to check if you are going ahead anyway.
What the meeting does not change
It does not put anything on the bulks list. Listing requires notice-and-comment rulemaking and a final rule, and FDA has proposed no rule. None of the seven is listed. [4] [5]
It does not approve any drug. Bulks list eligibility means a licensed pharmacy may compound the substance for an individual patient with a prescription. It is not an FDA finding that the peptide works for any condition, and compounded products are not FDA approved.
It does not change the evidence. Our evidence grades are based on indexed studies, not votes. Four of the six peptides the committee voted for are graded animal only, and semax and epitalon are graded human observational:
- BPC-157: rodent data, including faster Achilles tendon healing in rats, mostly from one research group. A 2019 review concluded human trials are needed before clinical claims can be made. [8] [9]
- KPV: two 2008 mouse colitis studies; no indexed human trial. [10]
- TB-500: FDA's briefing found no article in which TB-500 was given to humans and no animal study of TB-500 for wound healing. The rat wound closure result often cited for it used full-length thymosin beta-4, which FDA says is not the same substance. [11] [22]
- MOTS-c: mouse metabolic studies; no human interventional trial. [12]
- Semax: open-label Russian clinical studies in stroke without independent replication. [13]
- Epitalon: lifelong mouse studies, plus two Russian human studies that reported higher melatonin output without stating their design or sample size. [14] [23] [24]
If you are weighing BPC-157 against TB-500 specifically, our side-by-side comparison shows that neither has human evidence for injury healing.
It does not open 503B outsourcing. Outsourcing facilities follow a different pathway and a different list. [7]
It does not change WADA status. BPC-157, KPV, and epitalon remain prohibited for tested athletes under WADA's non-approved substances section, MOTS-c remains named under section S4.4 as a metabolic modulator, and TB-500 is named under peptide hormones and growth factors. [21]
DSIP is the instructive case
DSIP (delta sleep-inducing peptide) is the only peptide of the seven with randomized, placebo controlled human trials, yet FDA's briefing recommended against listing it too, and FDA has not posted the committee's vote. [2] Its trials are small, date from 1987 to 1992, and reported effects that were short-lived or inconsistent. [15] The lesson is that a randomized design alone does not carry a nomination; FDA looks at the size, consistency, and safety picture of the whole record. DSIP is not on the bulks list and FDA has proposed no rule, so we list it as not eligible.
What to watch next
- The HHS draft policy. On October 28, 2026, HHS released a draft enforcement discretion policy for the first six, with comments open through November 13, 2026. See our explainer. [1]
- Any FDA rulemaking. FDA has proposed no rule and is not bound by PCAC votes. Any rule would appear in the Federal Register with a comment period.
- State board guidance. Some boards issue their own notices after federal changes. Our state pages track board names and rules.
- New human data. A published trial would change a grade faster than any vote.
Treat each of these peptides as what it is today: an unapproved substance that is not on the 503A bulks list and that FDA's own briefing recommended against listing, with, for most, animal-only evidence. For the first six, HHS's draft policy is enforcement discretion, not approval; DSIP is not covered.
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Pages referenced in this article
- IndexRegulatory tracker
- PeptideBPC-157
- PeptideKPV
- PeptideTB-500
- PeptideMOTS-c
- PeptideSemax
- PeptideEpitalon
- PeptideDSIP (delta sleep-inducing peptide)
- ComparisonBPC-157 vs TB-500
- IndexState legal guides
Frequently asked questions
Is BPC-157 legal to compound after the July 2026 PCAC meeting?
The meeting itself did not make it lawful. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). FDA has proposed no rule, and BPC-157 is not on the 503A bulks list. On October 28, 2026, HHS released a draft enforcement discretion policy that covers single-ingredient BPC-157 under strict conditions. It is not an FDA approval or a listing, it is not binding, and state law still applies. [1] [2] [3] [4] [5]
Why did FDA's briefing recommend against DSIP when it has randomized human trials?
FDA's briefing recommended against listing DSIP, and FDA has not posted the committee's vote. DSIP's trials are small, date from 1987 to 1992, and reported short-lived or inconsistent effects on sleep, so having randomized data did not settle whether it is safe and effective. [2] [15]
Does the meeting change anything for athletes?
No. FDA compounding decisions and the WADA Prohibited List are separate. BPC-157, KPV, and epitalon fall under WADA's non-approved substances section, MOTS-c is named under section S4.4 as a metabolic modulator, and TB-500 is named under peptide hormones and growth factors. [21]
Can an outsourcing facility (503B) make these peptides?
The meeting concerned the 503A bulks list used by traditional compounding pharmacies. Our records show none of the six as eligible for 503B outsourcing, which runs on a separate list. [2] [7]
Sources
Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.
- [1]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
- [2]FDA: Pharmacy Compounding Advisory Committee (July 23 to 24, 2026 meeting on peptide nominations)FDA, 2026
- [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [5]Federal Register: List of bulk drug substances that can be used to compound drug products in accordance with section 503A (final rule, February 19, 2019)Federal Register, 2019
- [6]21 U.S.C. 353a, Pharmacy compounding (Office of the Law Revision Counsel)
- [7]FDA: Information for outsourcing facilities (section 503B)FDA
- [8]Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011PubMed 21030672, 2011
- [9]Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019PubMed 30915550, 2019
- [10]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008